FOSHAN, GUANGDONG, CHINA, January 13, 2026 /EINPresswire.com/ -- The construction industry is experiencing a materials ...

The unit is part of a broader push to better integrate cyber, EW, and other non-destructive effects into missions, leaders ...

Officials said that cyber capabilities are expected to play a central role in future U.S. military undertakings.

Optical metasurfaces, with their ultra-thin and lightweight properties, are driving the miniaturization and planarization of optical systems. However, their development from unit-cell design to system ...

CSL Seqirus, the vaccine unit of Australian biotech CSL, has signed a pact to provide Saudi Arabia with cell-based influenza shots and help establish its production in-country. The move forms part of ...

Galapagos (NASDAQ:GLPG) ADRs dropped ~13% in the premarket on Tuesday after the Belgian biotech announced plans to wind down its cell therapy business, impacting roughly 365 employees in Europe, the U ...

Galapagos is planning to wind down its cell therapy business, completing a whiplash change that saw the biotech go from focusing on the modality to ditching it in six months. Belgium-based Galapagos ...

(Reuters) -Novo Nordisk has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday. Bloomberg News first reported on ...

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

Ozempic maker Novo Nordisk (NVO) is closing its cell therapy division as part of a major restructuring drive initiated under the company’s new CEO, Mike Doustdar, Bloomberg News reported on Thursday, ...

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...